Prodrug Development of Biased N-Alkylpyridazinones for the Acute Intravenous Treatment of Myocardial Ischaemia-Reperfusion Injury

用于急性静脉注射治疗心肌缺血再灌注损伤的偏向 N-烷基哒嗪酮类前药开发

• 批准号: nhmrc : GNT1155527
• 负责人: Dr Chengxue Qin
• 金额: $ 67.71万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/prodrug-development-biased-reperfusion-injury/1349192
• 关键词: Prodrug; Development; Biased; Alkylpyridazinones; Acute

The leading cause of death worldwide, accounting for 30% of all global deaths, is cardiovascular disease. This figure has heart attack and associated changes heart oxygen levels as a major injury-causing component. We have discovered a potential treatment that is limited by its solubility properties. In this R&D plan we will develop soluble preclinical progression drug candidates for the treatment of oxygen-related heart attack injury.

心血管疾病是全球死亡的主要原因，占全球死亡总数的30%。这个数字有心脏病发作和相关的变化心脏氧水平作为一个主要的伤害造成的组成部分。我们已经发现了一种潜在的治疗方法，但受到其溶解性的限制。在这项研发计划中，我们将开发可溶性临床前进展候选药物，用于治疗氧相关心脏病发作损伤。